Although multiple critical steps are taken to minimize the risk of infection from transfusion of blood or blood products in developed countries, this risk can never be entirely eliminated. In Canada, the risks of noninfectious transfusion reactions, such as transfusion-related acute lung injury and major allergic or anaphylactic reactions, are greater than that of infection. This updated practice point provides an overview of transfusion infection risks in Canada. Infectious agents, systemic conditions, donor and recipient factors, and collection and infusion techniques are considered. Suggestions are offered to improve both system and process, and to help practitioners who are discussing informed consent with patients and parents before administering blood or a blood product.
In Canada and other developed countries, many steps are taken to minimize the risk of infection from transfusion of blood or blood products [1] , but this risk is never reduced to zero because these biological products are taken from living donors who are never 'germ free'. [2] However, the risk of noninfectious transfusion reactions, such as transfusion-related acute lung injury (TRALI) and major allergic or anaphylactic reactions, are greater than that of infection. [3] This updated practice point provides an update on transfusion infection risks in Canada. It replaces a 2006 note, [4] and may be helpful to practitioners in discussion with patients and parents toward informed consent before administering blood or blood products.
Steps to prevent infections from blood transfusion
Restrictive transfusion policies and effective blood conservation programs A crucial step in enhancing safety is to assess carefully whether the patient is likely to benefit from administering blood or a blood product (ie, that potential benefits outweigh the potential risks). [3] This assessment is key in paediatrics because many adverse events in this age group are due to human error, such as overtransfusion or the inappropriate transfusion of neonates. [3] Studies of adults in critical care settings have shown that a restrictive transfusion policy is at least as effective as a liberal transfusion strategy in terms of outcome. [5] While outcomes of restrictive policies in neonatal and paediatric intensive care settings are not as clear-cut, preventative and/or intervention strategies that minimize the need for transfusion are recommended. [6] - [8] Evidence-based effective policies for donor selection, screening, product collection, testing and infusion While any infectious agent that has a blood phase has the potential to be transmitted by transfusing blood or blood products, the probability of infection in the recipient depends upon a number of factors, including: [9] • the prevalence of the agent in the blood of the donor population;
• the tolerance of the agent to blood handling, storage and manufacturing processes;
• the infectivity and pathogenicity of the agent;
• the recipient's health and immune status; 0 |
• the effectiveness of donor screening or donor testing for the agent; and
• the effectiveness of aseptic technique procedures used to collect the blood or blood product from the donor and to infuse the product into the recipient.
In Canada, the infectious disease risks of transfusion are minimized through multiple steps, including: blood collection from volunteer unpaid donors; donor interview and selection protocols; careful aseptic technique procedures for collection and infusion; [10] [11] the diversion of the first 40 mL of blood collected into a diversion pouch [12] (ie, not used for transfusion); donor screening by serological and other tests, including bacterial detection in platelets [13] (Table 1 ); viral inactivation procedures used in manufacturing plasma-derived products (Table 2 ); [9] and leukocyte reduction techniques that reduce the transmission risk of white cell-associated viruses, such as cytomegalovirus (CMV). [9] Unfortunately, the solvent/detergent and inactivation by heat procedures noted in Table 2 Table 3 identifies specific inactivation steps in the manufacture of different plasma-derived products that decrease viral infection risks. Of note, the majority of Factor VIII and Factor IX used in Canada are recombinant products, not plasma-derived, and hence do not have the infectious risks of a blood product. Of note, the majority of Factor VIII and Factor IX used in Canada are recombinant products, not plasma-derived, and hence do not have the infectious risks of a blood product.
The risk of bacterial contamination of platelets is greater than for red cells because platelets are stored at room temperature (22°C ± 2°C), which supports bacterial pathogen multiplication. [14] [15] Initial aliquot diversion and bacterial detection have decreased the risk significantly, [13] as has the automated culture of platelet components, but bacterial contamination of platelet concentrates remains a concern. [16] The risk of bacterial contamination of frozen components, such as fresh frozen plasma and cryoprecipitates, is much lower because the usual microbes (Table 4) are killed by freezing and other storage conditions. While plasma contamination from the water bath used to thaw the product was a problem in the past, the use of microwave techniques or of appropriate plastic covering designed specifically for this purpose have minimized the risk. [17] Isolation of filtrate ± isolation of filtrate IV ± isolation of filtrate d ± pasteurization ± cold ethanol fractionation ± heated treated IVIG products + Yes Cold ethanol fractionation, solvent/detergent ± caprylate ± column chromatography ± low pH treatment ± nanofiltration ± heat treatment ± octanoic acid fractionation ± depth filtration ± virus filtration IMIG + Yes Cold ethanol fractionation, solvent/detergent ± heat inactivation ± precipitation filtration ± ultra filtration ± diafiltration Specific antibody products § + Yes Cold ethanol fractionation or ion exchange column chromatography, solvent/ detergent, virus filtration ± heat inactivation Anion-exchange column chromatography ± Planova 20N Virus Filter ± solvent/detergent ± cold ethanol fractionation ± heat inactivation ± precipitation filtration ± ultra filtration ± diafiltration 
*Human T-lymphotropic viruses (HTLV) type I/II are cell-associated viruses, so they are not found in manufactured plasma-derived products and serological screening of source plasma is not required. Similarly, cytomegalovirus (CMV) is primarily cell-associated, and the manufacturing processes remove risk; † Hence the risk of transmission of infection from cryoprecipitate is similar to the risk from blood and blood products, and greater than from plasma-derived manufactured products; ‡ Very few patients in Canada are treated with plasma-derived

Adverse transfusion events in Canada
The Transfusion Transmitted Injuries Surveillance System (TTISS) (<www.phac-aspc.gc.ca/hcai-iamss/tti-it/ index-eng.php>) now captures more than 80% of all transfusions in Canada, providing national data on transfusion transmitted injuries (ie, infectious diseases and noninfectious adverse events). The TTISS report for the year 2006 noted nine deaths for a rate of 1:130,122 units transfused; the reported rate of adverse events per product infused increased to 1:2950, up from 1:4091 in 2005. [18] The increase in the rate of reported adverse events was primarily due to increased recognition and reporting of transfusion-associated circulatory overload cases, regardless of their severity. Table 5 summarizes the types of reactions with blood product transfused for the 420 events reported in 2006, showing that the most common events were: transfusion-associated circulatory overload (46.2% of serious adverse events); severe/anaphylactic/anaphylactoid reactions (15.9%); hypotensive reaction (11.9%); and transfusion-related acute lung injury (8.1% + possible 1.9%). [18] Only five cases of bacterial contamination were reported for a rate of 1:292,775 units transfused. The TTISS program continues to verify a high degree of safety in the Canadian blood system and a very small risk of bacterial contamination, although both allergic/anaphylactic reactions and transfusion overload remain concerns.
Estimated per unit risks of bacterial, parasitic and viral contamination of blood and blood products
The estimated per unit risks of contamination in blood, blood products and manufactured plasma-derived products in Canada for a number of viral, bacterial, parasitic, prion and tick-borne agents are presented in Table 6 and Table 7 . As the data in these Tables show, the risks of transmitting infectious agents by blood, and especially by manufactured plasma-derived products, are extremely low in Canada. For context, a 1:3,000,000 risk is similar to that of being hit by lightning.
The importance of documenting transfusions
No national electronic record of transfusions yet exists to facilitate potential future trace-back programs for a new transmissible agent. Therefore, it is important to ensure that:
• transfused patients are aware they have received blood, blood products or manufactured plasma-derived products;
• the discharge or outpatient note adequately documents these transfusions, recording label code numbers for specific products; and
• hospital blood banks have such records.
Resources
Expanded discussion on the infectious diseases risks of transfusing blood and blood products can be found at the following websites:
• 
